Under the "slimming mode" of pharmaceutical companies, the demand for professional talents will become more and more vigorous

In recent years, domestic pharmaceutical companies have opened a "slimming mode", through framework restructuring, significant layoffs, to reduce countless costs, such as Eisai, Biogen, Novartis, Sanofi, Merck, Gilead, Daiichi Sankyo and other pharmaceutical companies have released layoffs
one after another this year 。 Under the wave of layoffs in pharmaceutical companies, the demand for professional talents will become more and more strong (Image source: Pharmaceutical Network) For example, on October 24, Dutch medical device manufacturer Philips issued a statement announcing urgent actions to improve performance, including the immediate layoff of about 4,000 employees worldwide, and about 300 million euros are expected to be raised in the next few quarters
.
Based on Philips' total employees of 78,000 last year, the layoffs accounted for more than
5% of the company's total workforce.
On October 23, it was reported that GreenLight Biosciences plans to integrate the "platform team" into their respective teams for human health and plant health, which will be accompanied by a 25% staff cut
.
It is worth mentioning that the reduction in headcount is expected to bring the company about $13 million in cost savings
by 2023.
On October 21, Johnson & Johnson will lay off more than 60 positions
in the New York office.
Johnson & Johnson reported "factory layoffs" to the WARN system in New York, noting that 64 layoffs will be made from January 13 to January 26, 2023.
.
.
Of course, not only multinational companies, but also domestic pharmaceutical companies are not happy, and the news of layoffs, disbandment of teams, and salary cuts is also endless
.
On August 19, Hengrui Pharmaceutical released a half-year report showing that the company's sales personnel decreased by more than 2,300 in the first half of
this year.
The company also mentioned in the report that "further streamline sales personnel, continue to reduce sales operating costs, and improve sales operation efficiency
.
" In addition, Dongguang Pharmaceutical last disclosed that the total number of employees was 3,616, which is 1,150 fewer than a year ago
.
At present, from the perspective of the motivation of major pharmaceutical companies to lay off employees, there are three main points, first of all, in the context of intensifying competition in the pharmaceutical market, pharmaceutical companies are actively adjusting their development strategies, so the personnel brought by them have become inevitable
.
Secondly, in recent years, labor costs have continued to rise, pharmaceutical companies are facing the challenge of cost control, and with the advancement of new technologies such as digitalization and automation, digital production, digital operation and management have gradually entered pharmaceutical factories, resulting in pharmaceutical companies choosing to lay off employees
.
In addition, due to the influence of policies such as centralized procurement and medical insurance fee control, pharmaceutical companies have opened up channels for entering hospitals, saving commercial promotion costs, so the demand for sales personnel has decreased
.
Compared with multinational companies, Chinese companies lay off more jobs for third reasons
.
However, analysts also pointed out that layoffs are to improve the profits of pharmaceutical companies, not necessary
.
The growth of pharmaceutical companies' profits still needs to be carried out
by increasing sales revenue, improving gross profit, reducing costs, and improving net profit.
At present, it can be clearly seen that many enterprises will recruit some new personnel who can bring higher benefits to the enterprise while reducing personnel, such as technical positions
such as research and development.
Pfizer, for example, announced its digital layout and decided to cut hundreds of sales jobs in the United States and India, while saying it would add about half of digital-related jobs
.
According to the 2022 semi-annual report of Chutian Technology, the number of technical R&D personnel in the first half of the year increased by more than 650 compared with the same period, and the number of technical R&D personnel of the group during the reporting period was nearly 2,000
.
In addition to R&D and technical personnel, there is still a huge demand
for professional sales personnel in pharmaceutical companies in 2022.
Since the beginning of this year, Sino-US East China, Menarini (China), Fosun Pharma, etc.
are recruiting professionals for different positions, including academic information specialist, medical information communication specialist, regional manager, promotion manager, medical representative, etc
.
It can be seen from the above that for pharmaceutical companies, professional technology, sales and other talents
are more needed than layoffs.
The industry expects that in the future, while accelerating innovation and transforming marketing strategies, the demand for professional talents in line with the development of enterprises will become more and more vigorous
.
Among them, especially the R&D personnel
.
After all, the market "smashed" by heavy marketing, if there is no support from hardcore products, can only be prosperous, only to create a hardcore technical "moat" can continue to inject vitality into the product
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.